RTTNews | Jan 4, 2022 10:30AM EST

10:30 Tuesday, January 4, 2022 (RTTNews.com) - Shares of Immix Biopharma, Inc. (IMMX) are gaining nearly 25% on Tuesday morning. The other day, the U.S. Food and Drug Administration granted Rare Pediatric Disease (RPD) designation for Immix Biopharma's IMX-110 for the treatment of a life-threatening form of pediatric cancer in children, rhabdomyosarcoma.

IMMX is currently trading at $7.18, up $1.40 or 24.31%, on the Nasdaq.

IMX-110, an investigational product, is currently being evaluated in a Phase 1b/2a clinical trial. It is a tissue-specific therapeutic that simultaneously attacks all 3 components of the tumor micro-environment, severing the critical lifelines between the tumor and its metabolic and structural support.

The FDA grants Rare Pediatric Disease designation for serious and life-threatening diseases that primarily affect children aged 18 years or younger and impact fewer than 200,000 people in the U.S.

Rhabdomyosarcoma is a high-grade, malignant neoplasm, the most common soft tissue sarcoma in pediatric and adolescent populations and which rarely occurs in adults. The prevalence of RMS in the United States is approximately 20,000 children of all ages. The five-year survival rate ranges from 20% to 30% for children in the high-risk group where cancer spreads widely in the body.

Read the original article on RTTNews ( https://www.rttnews.com/3252691/immix-biopharma-gains-25-as-its-pediatric-cancer-treatment-gets-fda-s-rpd-designation.aspx)

For comments and feedback: contact editorial@rttnews.com

Copyright(c) 2022 RTTNews.com All Rights Reserved